DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2015/0290152 A1 KELNER (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2015/0290152 A1 KELNER (43) Pub US 20150290152A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0290152 A1 KELNER (43) Pub. Date: Oct. 15, 2015 (54) AFFINITY MEDICANT CONJUGATE (52) U.S. Cl. (71) Applicant: AF CHEMICALS, LLC CPC ........... A6 IK31/19 (2013.01); A61K 47/48.123 (2013.01); A61 K3I/I22 (2013.01); A61 K (72) Inventor: MICHAEL KELNER, LA JOLLA, CA 47/48384 (2013.01); A61K 47/48269 (2013.01) (US) (21) Appl. No.: 14/684,218 (22) Filed Apr. 10, 2015 In an embodiment of the invention, a composition for treating 1C p 9 a cell population comprises an Affinity Medicant Conjugate Related U.S. Application Data (AMC). The medicant moiety can be a toxin including an (60) Provisional application No. 61/978,195, filed on Apr. acylfulvene or a drug moiety. The affinity moiety can be an 10, 2014. antibody, a binding protein, a steroid, a lipid, a growth factor, Publication Classification a protein, a peptide or nonpeptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers (51) Ek'.L/19 (2006.01) that can be directed to cysteine, arginine or lysine residues A6 IK3I/22 (2006.01) based on solution pH allow greater flexibility in preserving A6 IK 47/48 (2006.01) and/or generating specific epitopes in the AMC. Patent Application Publication Oct. 15, 2015 Sheet 1 of 71 US 2015/0290152 A1 Figure 1 AM—LU — MM 1100 1200 1300 1 OOO Patent Application Publication Oct. 15, 2015 Sheet 2 of 71 US 2015/0290152 A1 Figure 2A Figure 2B 2C Figure 2D Figure 2E 1. R R R3 R1 6 R3 2 R2 R4ORs R2 ...R5 . O O Figure 2F Figure 2G Patent Application Publication Oct. 15, 2015 Sheet 3 of 71 US 2015/0290152 A1 Fl gure 2H F gure 2I (I) (H) -(O R2 R;-( O R2 R 1. X-R 5 1 R4 R4 Ró ró O O Figure 2J RdS Figure 2N X /s R 1s R1 r/ R R4 Figure 20 III IIIRs III R RO RO O O Patent Application Publication Oct. 15, 2015 Sheet 4 of 71 US 2015/0290152 A1 Figure 2P R2 R-(N R7 R Figure 2R Patent Application Publication Oct. 15, 2015 Sheet 5 of 71 US 2015/0290152 A1 Figure 2S a R3 R-N Figure 2V 2 Patent Application Publication Oct. 15, 2015 Sheet 6 of 71 US 2015/0290152 A1 Figure 3A Ab —LU— MM 1110 12OO 1300 1 OO1 Patent Application Publication Oct. 15, 2015 Sheet 7 of 71 US 2015/0290152 A1 Figure 3B Gf —LU — MM 1120 12OO 1300 1 OO2 Patent Application Publication Oct. 15, 2015 Sheet 8 of 71 US 2015/0290152 A1 Figure 4 Tumor Cell line 2 hr. 4 8 h r Myeloid leukemias Yes Yes Breast CarcinomaS Yes Yes Epidermoid Yes Yes Ovarian Yes Yes Lung CarcinomaS Yes Yes PrOState Carcinomas Yes Yes B Cell leukemiaS NO Yes T Cell leukemias NO Yes Fibroblasts (normal) NO Yes Patent Application Publication Oct. 15, 2015 Sheet 9 of 71 US 2015/0290152 A1 Figure 5 Unique DNA Damage Profile Other Drugs UV Illudin S XP-A H H H XP-B O -- -- XP-C H H O XP-D O H H XP-E H H O XP-F H H H CS-A +/- -- ---- CS-B +/- H HH ERCC1 H H H ERCC5 -- -- -- Indicates novel mechanism of action versus other chemotherapeutic agents Patent Application Publication Oct. 15, 2015 Sheet 10 of 71 US 2015/0290152 A1 Figure 6 S.- : Cytarabine MTO oxostic T o:-- royen Time (days) Patent Application Publication Oct. 15, 2015 Sheet 11 of 71 US 2015/0290152 A1 Figure 7 Mechanism Resistance to Irofulven Gp170/MDR1 NO Gp180/MRP NO Topoisomerase I NO Topoisomerase II NO LRP(vault) NO Thiol Content NO DNA repair (?) NO Myc expression NO Bcl-2 expression NO BRCA Status NO p53 status NO p21 Status NO Patent Application Publication Oct. 15, 2015 Sheet 12 of 71 US 2015/0290152 A1 Patent Application Publication Oct. 15, 2015 Sheet 13 of 71 US 2015/0290152 A1 Patent Application Publication Oct. 15, 2015 Sheet 14 of 71 US 2015/0290152 A1 Figure 10A Figure 10B CC Figure 10C Patent Application Publication Oct. 15, 2015 Sheet 15 of 71 US 2015/0290152 A1 O Figure 11 A -l H O - Patent Application Publication Oct. 15, 2015 Sheet 16 of 71 US 2015/0290152 A1 Patent Application Publication Oct. 15, 2015 Sheet 17 of 71 US 2015/0290152 A1 Figure 13A O Patent Application Publication Oct. 15, 2015 Sheet 18 of 71 US 2015/0290152 A1 Figure 14A O O N Sv?.o/V O YY O O O O HGS N1 O O O Figures 14B 'vy. O O O v OM Y. S/N HN-NH O to Figure 14C Patent Application Publication Oct. 15, 2015 Sheet 19 of 71 US 2015/0290152 A1 Figure 15A R1 R2 X O S-F C R3 R4 Figure 15B R1 R-FS X No y R2 C R3 R4 Figure 15C R1 R2 X R3 C R Patent Application Publication Oct. 15, 2015 Sheet 20 of 71 US 2015/0290152 A1 Figure 16A Figure 16B O OH R7 O Oi-f 2. Figure 16C Figure 16D Patent Application Publication Oct. 15, 2015 Sheet 21 of 71 US 2015/0290152 A1 Figure 17A Figure 17B Figure 17C Patent Application Publication Oct. 15, 2015 Sheet 22 of 71 US 2015/0290152 A1 100 S-xoSox$xoS N & - S - $88.8s 0.1 |--AAAAAA&accoss 1. 10 100 1000 10000 Antibody (ug/mL) Figure 18 Patent Application Publication Oct. 15, 2015 Sheet 23 of 71 US 2015/0290152 A1 100 1910 . D CM O 1920 Q SN 7, 1930 -0 1940 10 1. 10 100 Antibody (ug/mL) Figure 19A Patent Application Publication Oct. 15, 2015 Sheet 24 of 71 US 2015/0290152 A1 10 FigureO 19B s D 2 1950 & 20 1955 1-1 100 200 300 Antibody (ug/mL) 100 s Figure 19C s CM) & 6 roo - Antibody (ug/mL) Patent Application Publication Oct. 15, 2015 Sheet 25 of 71 US 2015/0290152 A1 100 Figure 19D S5 O 100 200 300 Antibody (ug/mL) 100 Figure 19E . 1980 D s CM) S50 1985 100 200 300 Antibody (ug/mL) Patent Application Publication Oct. 15, 2015 Sheet 26 of 71 US 2015/0290152 A1 Figure 21 A Os-N- O O O Figure 21B O O HOt, O O -s- ) { O Q HO, O Figure 21C Patent Application Publication Oct. 15, 2015 Sheet 27 of 71 US 2015/0290152 A1 Figure 22A Figure 22C Figure 22D Patent Application Publication Oct. 15, 2015 Sheet 28 of 71 US 2015/0290152 A1 OH HOt, HO, O O FIGURE 20AA OO1) FIGURE 20AB (OO2) Br HOn , , O FIGURE 20AC (003) FIGURE 20AD (004) HOt, O FIGURE 20AE (005) FIGURE 20AF (006) os-os O HOt, O FIGURE 20AG (007) FIGURE 20AH (008) Patent Application Publication Oct. 15, 2015 Sheet 29 of 71 US 2015/0290152 A1 29 -2O HO, HOt, O O FIGURE 20A (OO9) FIGURE 20AJ O1O) 2O NO2 HO, HOt, O O FIGURE 20AK (011) FIGURE 20AL (O12) O FIGURE 20AM (013) FIGURE 20AN (014) OH OEt ACO1, HO, O O FIGURE 20AO (O15) FIGURE 20AP (016) Patent Application Publication Oct. 15, 2015 Sheet 30 of 71 US 2015/0290152 A1 O OfructOSe 'OH HO, O is O O FIGURE 20AO (O17) FIGURE 20AR (018) OH N-N --oh HOt, HO, O O FIGURE 20AS (O19) FIGURE 20AT (020) oséole OY-1SoH HO, HO1, O O FIGURE 20AU (O21) FIGURE 20AV (022) HO/, HOt, O O FIGURE 20AW (O23) FIGURE 20AX (024) Patent Application Publication Oct. 15, 2015 Sheet 31 of 71 US 2015/0290152 A1 S-N-CO2Me *C) HOt, HO, O O FIGURE 20AY (025) FIGURE 20AZ (O26) on-op O-I-Ph O O HOt, HO1, O O FIGURE 20BA (027) FIGURE 20BB (O28) SN-COH S-N-CO2Me HOn , HOt, O O S1)CO-Me FIGURE 20BC (029) FIGURE 20BD (030) S-N-CO2Me OH HO/ HOf, OH O yco Me O FIGURE 20BE (031) FIGURE 20BF (032) Patent Application Publication Oct. 15, 2015 Sheet 32 of 71 US 2015/0290152 A1 OAC K O O FIGURE 20BG (O33) FIGURE 20BH (034) \2N^) HO HOI, O O FIGURE 20B (O35) FIGURE 20BJ (O36) CO2H S - COH2 HO1, HOI , O O FIGURE 20BK (O37) FIGUREGU 20BLO (O38) OMe OEt OMe OEt HO1, HOt, O O FIGURE 20BM (O39) FIGURE 20BN (040) Patent Application Publication Oct. 15, 2015 Sheet 33 of 71 US 2015/0290152 A1 2Y-2O OH TESO1, O O FIGURE 20BO (O41) FIGURE 20BP (O42) OTES OTES O O FIGURE 20BO (043) FIGURE 20BR (O44) OAC HO, O FIGURE 20BT (O46) HO, FIGURE 20BV (O48) Patent Application Publication Oct. 15, 2015 Sheet 34 of 71 US 2015/0290152 A1 HOt, O FIGURE 20BW (O49) FIGURE 20BX (O5O) FIGURE 20BY (O51) FIGURE 20BZ (O52) os-No-N-Br HOt. O FIGURE 20OA (O53) CH - S O i-K)-oh OH S R O FIGURE 20OC (O55) FIGURE 20OD (O56) Patent Application Publication Oct. 15, 2015 Sheet 35 of 71 US 2015/0290152 A1 FIGURE 20OE (057 FIGURE 20OF (O58) O OH Ku OH FIGURE 20OG (O59) FIGURE 20OH O6O) HO1, OH O O FIGURE 20O (O61) FIGURE 20O (062) OH COOH sus NHAC HOt, OH O FIGURE25 20CK (O63) FIGURE 20OL (064) Patent Application Publication Oct. 15, 2015 Sheet 36 of 71 US 2015/0290152 A1 H OS N- 2 O OSN 2.
Load more

Recommended publications
  • Hydroxylation of the Eukaryotic Ribosomal Decoding Center Affects Translational Accuracy
    Hydroxylation of the eukaryotic ribosomal decoding center affects translational accuracy Christoph Loenarza,1, Rok Sekirnika,2, Armin Thalhammera,2, Wei Gea, Ekaterina Spivakovskya, Mukram M. Mackeena,b,3, Michael A. McDonougha, Matthew E. Cockmanc, Benedikt M. Kesslerb, Peter J. Ratcliffec, Alexander Wolfa,4, and Christopher J. Schofielda,1 aChemistry Research Laboratory and Oxford Centre for Integrative Systems Biology, University of Oxford, Oxford OX1 3TA, United Kingdom; bTarget Discovery Institute, University of Oxford, Oxford OX3 7FZ, United Kingdom; and cCentre for Cellular and Molecular Physiology, University of Oxford, Oxford OX3 7BN, United Kingdom Edited by William G. Kaelin, Jr., Harvard Medical School, Boston, MA, and approved January 24, 2014 (received for review July 31, 2013) The mechanisms by which gene expression is regulated by oxygen Enzyme-catalyzed hydroxylation of intracellularly localized are of considerable interest from basic science and therapeutic proteins was once thought to be rare, but accumulating recent perspectives. Using mass spectrometric analyses of Saccharomyces evidence suggests it is widespread (11). Motivated by these cerevisiae ribosomes, we found that the amino acid residue in findings, we investigated whether the translation of mRNA to closest proximity to the decoding center, Pro-64 of the 40S subunit protein is affected by oxygen-dependent modifications. A rapidly ribosomal protein Rps23p (RPS23 Pro-62 in humans) undergoes growing eukaryotic cell devotes most of its resources to the tran- posttranslational hydroxylation. We identify RPS23 hydroxylases scription, splicing, and transport of ribosomal proteins and rRNA as a highly conserved eukaryotic subfamily of Fe(II) and 2-oxoglu- (12). We therefore reasoned that ribosomal modification is a tarate dependent oxygenases; their catalytic domain is closely re- candidate mechanism for the regulation of protein expression.
    [Show full text]
  • Enzymatic Encoding Methods for Efficient Synthesis Of
    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
    [Show full text]
  • Amino Acids by GRAHAM C
    1 Amino Acids BY GRAHAM C. BARRETT 1 Introduction The literature of 1996 is covered in this Chapter, which aims to report and appraise newly-published knowledge of the chemistry of amino acids. Biological aspects are given prominence only where the chemical interest is enhanced by explaining the life science context. Literature citations forming the basis for this Chapter have been obtained from Chemical Abstracts (Volume 124, Issue no. 11 to Volume 126, Issue no. 9 inclusive), and from papers consulted in major Journals that have consistently been used by authors of relevant material. The expanding volume of the relevant literature continues to demand ingenuity in somehow getting a litre of wholesome nourishment into the half-litre pot that this Chapter represents, and restrictions have been placed on citations of the patent literature and material of a more routine nature. Authors who repeat- publish and over-fragment their material are responsible to a significant extent for the ever-increasing number of references for this Chapter, and this Reviewer’s conscience rests easily when grouping such papers together without detailed comment on each of them. As usual, the carboxylic acid grouping is understood to be implied by the term ‘amino acid’ for the purposes of this Chapter, though interest in boron and phosphorus oxy-acid analogues and also in sulfonic acid analogues, is continuing to grow. Methods applicable .for the synthesis of a-aminoalkaneboronic acids (Refs. 65, 146, 147), a-aminoalkanesulfonic acids (Refs. 154, 845), and a- aminoalkanephosphonic acids and other phosphorus oxyacids (Refs. 32, 62, 80, 82, 85, 87, 88, 152, 326, 374, 437, 843) are usually derived from extensions of standard methods in the amino acid field, and representative examples of syntheses of amino oxyacid analogues are described, side-by-side with corresponding methods for amino carboxylic acids, in appropriate locations in this Chapter.
    [Show full text]
  • Amino Acids by G.C.BARRETT
    1 Amino Acids By G.C.BARRETT 1 Introduction The chemistry and biochemistry of the amino acids as represented in the 1992 literature, is covered in this Chapter. The usual policy for this Specialist Periodical Report has been continued, with almost exclusive attention in this Chapter, to the literature covering the natural occurrence, chemistry, and analysis methodology for the amino acids. Routine literature covering the natural distribution of well-known amino acids is excluded. The discussion offered is brief for most of the papers cited, so that adequate commentary can be offered for papers describing significant advances in synthetic methodology and mechanistically-interesting chemistry. Patent literature is almost wholly excluded but this is easily reached through Section 34 of Chemical Abstracts. It is worth noting that the relative number of patents carried in Section 34 of Chemical Abstracts is increasing (e.g. Section 34 of Chem-Abs., 1992, Vol. 116, Issue No. 11 contains 45 patent abstracts, 77 abstracts of papers and reviews), reflecting the perception that amino acids and peptides are capable of returning rich commercial rewards due to their important physiological roles and consequent pharmaceutical status. However, there is no slowing of the flow of journal papers and secondary literature, as far as the amino acids are concerned. The coverage in this Chapter is arranged into sections as used in all previous Volumes of this Specialist Periodical Report, and major Journals and Chemical Abstracts (to Volume 118, issue 11) have
    [Show full text]
  • Conditioning Medicine
    Conditioning Medicine www.conditionmed.org REVIEW ARTICLE | OPEN ACCESS A new pharmacological preconditioning-based target: from drosophila to kidney transplantation Michel Tauc1*, Nicolas Melis1*, Miled Bourourou2, Sébastien Giraud3, Thierry Hauet3, and Nicolas Blondeau2 One of the biggest challenges in medicine is to dampen the pathophysiological stress induced by an episode of ischemia. Such stress, due to various pathological or clinical situations, follows a restriction in blood and oxygen supply to tissue, causing a shortage of oxygen and nutrients that are required for cellular metabolism. Ischemia can cause irreversible damage to target tissue leading to a poor physiological recovery outcome for the patient. Contrariwise, preconditioning by brief periods of ischemia has been shown in multiple organs to confer tolerance against subsequent normally lethal ischemia. By definition, preconditioning of organs must be applied preemptively. This limits the applicability of preconditioning in clinical situations, which arise unpredictably, such as myocardial infarction and stroke. There are, however, clinical situations that arise as a result of ischemia-reperfusion injury, which can be anticipated, and are therefore adequate candidates for preconditioning. Organ and more particularly kidney transplantation, the optimal treatment for suitable patients with end stage renal disease (ESRD), is a predictable surgery that permits the use of preconditioning protocols to prepare the organ for subsequent ischemic/reperfusion stress. It therefore seems crucial to develop appropriate preconditioning protocols against ischemia that will occur under transplantation conditions, which up to now mainly referred to mechanical ischemic preconditioning that triggers innate responses. It is not known if preconditioning has to be applied to the donor, the recipient, or both.
    [Show full text]
  • Roles of Eukaryotic Initiation Factor 5A2 in Human Cancer Feng-Wei Wang1, Xin-Yuan Guan2, Dan Xie1
    Int. J. Biol. Sci. 2013, Vol. 9 1013 Ivyspring International Publisher International Journal of Biological Sciences 2013; 9(10):1013-1020. doi: 10.7150/ijbs.7191 Review Roles of Eukaryotic Initiation Factor 5A2 in Human Cancer Feng-wei Wang1, Xin-yuan Guan2, Dan Xie1 1. Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China. Collaborative Innovation Center of Cancer Medicine. 2. Department of Clinical Oncology, the University of Hong Kong, Hong Kong, China. Corresponding author: Dan Xie, M.D. Ph.D. Sun Yat-Sen University Cancer Center, State key laboratory of oncology in South China, Collaborative Innovation Center of Cancer Medicine, No. 651, Dongfeng Road East, 510060 Guangzhou, China. Tel: 86-20-87343192 Fax: 86-20-87343170 Email: [email protected]. © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2013.07.18; Accepted: 2013.09.26; Published: 2013.10.12 Abstract Eukaryotic initiation factor 5A (eIF5A), the only known cellular protein containing the amino acid hypusine, is an essential component of translation elongation. eIF5A2, one of the two isoforms in the eIF5A family, is reported to be a novel oncogenic protein in many types of human cancer. Both in vitro and in vivo studies showed that eIF5A2 could initiate tumor formation, enhance cancer cell growth, and increase cancer cell motility and metastasis by inducing epithelial-mesenchymal transition.
    [Show full text]
  • The Development and Improvement of Instructions
    INITIAL CHARACTERIZATION OF HUMAN SPERMINE OXIDASE A Thesis by PAUL RAMON JUAREZ Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE December 2008 Major Subject: Biochemistry INITIAL CHARACTERIZATION OF HUMAN SPERMINE OXIDASE A Thesis by PAUL RAMON JUAREZ Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Approved by: Chair of Committee, Paul F. Fitzpatrick Committee Members, Dorothy Shippen J. Martin Scholtz Head of Department, Gregory D. Reinhart December 2008 Major Subject: Biochemistry iii ABSTRACT Initial Characterization of Human Spermine Oxidase. (December 2008) Paul Ramon Juarez, B.S.; B.A., Texas A&M University-Corpus Christi Chair of Advisory Committee: Dr. Paul F. Fitzpatrick The flavoprotein spermine oxidase catalyzes the oxidation of spermine and oxygen to spermidine, 3-aminopropanol, and hydrogen peroxide. To allow mechanistic studies of the enzyme, methods have been developed to obtain large amounts of purified recombinant protein. The enzyme requires co-expression with chaperone proteins GroEL and GroES to remain soluble and active. Purification requires the use of a Ni- NTA and size exclusion column. Human spermine oxidase is a monomer with an extinction coefficient of 14000 M-1cm-1. The kinetic mechanism is ping pong. Therefore, oxygen is bound to the enzyme before spermidine is released. N1-Acetyl spermine is a slow substrate with kcat and kcat/Km values 2 and 3 orders of magnitude smaller than the values for spermine. Spermidine is a competitive inhibitor, and 1,8- diaminooctane (DAO) is an uncompetitive inhibitor.
    [Show full text]
  • A Novel Mouse Model for Inhibition of DOHH-Mediated Hypusine Modification Reveals a Crucial Function in Embryonic Development, P
    © 2014. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2014) 7, 963-976 doi:10.1242/dmm.014449 RESEARCH ARTICLE A novel mouse model for inhibition of DOHH-mediated hypusine modification reveals a crucial function in embryonic development, proliferation and oncogenic transformation Henning Sievert1, Nora Pällmann1,2,*, Katharine K. Miller3,*, Irm Hermans-Borgmeyer3, Simone Venz4, Ataman Sendoel5,6, Michael Preukschas1, Michaela Schweizer3, Steffen Boettcher6, P. Christoph Janiesch3, Thomas Streichert7, Reinhard Walther4, Michael O. Hengartner5, Markus G. Manz6, Tim H. Brümmendorf8, Carsten Bokemeyer1, Melanie Braig1, Joachim Hauber2, Kent E. Duncan3 and Stefan Balabanov1,6,‡ ABSTRACT factor 5A (eIF5A), represents an essential mechanism in the control The central importance of translational control by post-translational of proliferation of eukaryotic cells (Cooper et al., 1982). This modification has spurred major interest in regulatory pathways that modification leads to the activation of eIF5A and is mediated by control translation. One such pathway uniquely adds hypusine to deoxyhypusine synthase (DHS), which catalyses the transfer of a 4- eukaryotic initiation factor 5A (eIF5A), and thereby affects protein aminobutyl moiety of spermidine to the ε-amino group of Lys50 to synthesis and, subsequently, cellular proliferation through an form an intermediate residue, deoxyhypusine (Dhp50) (Park et al., unknown mechanism. Using a novel conditional knockout mouse 1981). Subsequently, deoxyhypusine hydroxylase (DOHH)
    [Show full text]
  • Function of Elongation Factor P in Translation
    Function of Elongation Factor P in Translation Dissertation for the award of the degree ”Doctor rerum naturalium“ of the Georg-August-Universität Göttingen within the doctoral program Biomolecules: Structure–Function–Dynamics of the Georg-August University School of Science (GAUSS) submitted by Lili Klara Dörfel from Berlin Göttingen, 2015 Members of the Examination board / Thesis Committee Prof. Dr. Marina Rodnina, Department of Physical Biochemistry, Max Planck Institute for Biophysical Chemistry, Göttingen (1st Reviewer) Prof. Dr. Heinz Neumann, Research Group of Applied Synthetic Biology, Institute for Microbiology and Genetics, Georg August University, Göttingen (2nd Reviewer) Prof. Dr. Holger Stark, Research Group of 3D Electron Cryo-Microscopy, Max Planck Institute for Biophysical Chemistry, Göttingen Further members of the Examination board Prof. Dr. Ralf Ficner, Department of Molecular Structural Biology, Institute for Microbiology and Genetics, Georg August University, Göttingen Dr. Manfred Konrad, Research Group Enzyme Biochemistry, Max Planck Institute for Biophysical Chemistry, Göttingen Prof. Dr. Markus T. Bohnsack, Department of Molecular Biology, Institute for Molecular Biology, University Medical Center, Göttingen Date of the oral examination: 16.11.2015 I Affidavit The thesis has been written independently and with no other sources and aids than quoted. Sections 2.1.2, 2.2.1.1 and parts of section 2.2.1.4 are published in (Doerfel et al, 2013); the translation gel of EspfU is published in (Doerfel & Rodnina, 2013) and section 2.2.3 is published in (Doerfel et al, 2015) (see list of publications). Lili Klara Dörfel November 2015 II List of publications EF-P is Essential for Rapid Synthesis of Proteins Containing Consecutive Proline Residues Doerfel LK†, Wohlgemuth I†, Kothe C, Peske F, Urlaub H, Rodnina MV*.
    [Show full text]
  • Structure and Function of Metallohydrolases in the Arginase- Deacetylase Family
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2016 Structure and Function of Metallohydrolases in the Arginase- Deacetylase Family Yang Hai University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Biochemistry Commons Recommended Citation Hai, Yang, "Structure and Function of Metallohydrolases in the Arginase-Deacetylase Family" (2016). Publicly Accessible Penn Dissertations. 1753. https://repository.upenn.edu/edissertations/1753 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1753 For more information, please contact [email protected]. Structure and Function of Metallohydrolases in the Arginase-Deacetylase Family Abstract Arginases and deacetylases are metallohydrolases that catalyze two distinct chemical transformations. The arginases catalyze the hydrolysis of the guanidinium group of arginine by using a hydroxide ion 2+ 2+ bridging the binuclear manganese cluster (Mn A-Mn B) for nucleophilic attack. The deacetylases catalyze the hydrolysis of amide bonds by using a mononuclear Zn2+-ion activated water molecule as the nucleophile. Despite the diverse functions, metallohydrolases of the arginase-deacetylase superfamily 2+ share the same characteristic α/β hydrolase core fold and a conserved metal binding site (the Mn B site in arginase corresponds to the catalytic Zn2+ site in deacetylase) which is essential for catalysis in both enzymes. We report crystal structure of formiminoglutamase from the parasitic protozoan Trypanosoma cruzi and confirm that formiminoglutamase is a Mn2+-requiring hydrolase that belongs to the arginase- deacetylase superfamily. We also report the crystal structure of an arginase-like protein from Trypanosoma brucei (TbARG) with unknown function. Although its biological role remains enigmatic, the 2+ evolutionarily more conserved Mn B site can be readily restored in TbARG through side-directed mutagenesis.
    [Show full text]
  • NIH Public Access Author Manuscript Nat Rev Cancer
    NIH Public Access Author Manuscript Nat Rev Cancer. Author manuscript; available in PMC 2013 October 23. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Nat Rev Cancer. 2013 August ; 13(8): 572±583. doi:10.1038/nrc3557. Serine, glycine and the one-carbon cycle: cancer metabolism in full circle Jason W Locasale1,2,3,4,* 1Biochemistry and Molecular Cell Biology, Cornell University, Ithaca NY 14850 2Genomics, Genetics and Development, Cornell University, Ithaca NY 14850 3Tri-Institutional Program in Computational Biology and Medicine 4Divison of Nutritional Sciences, Cornell University, Ithaca NY 14850 Abstract One carbon metabolism involving the folate and methionine cycle integrates carbon units from amino acids, including serine and glycine, and generates diverse outputs, such as the biosynthesis of lipids, nucleotides and proteins, the maintenance of redox status, and the substrates for methylation reactions. Long considered a `housekeeping' process, this pathway has been recently shown to have additional complexity. Recent genetic and functional evidence also suggests that hyperactivation of this pathway is a possible driver of oncogenesis and establishes links to cellular epigenetic status. Given the wealth of clinically available agents that target one carbon metabolism, these new findings could present opportunities for translation into precision cancer medicine. *correspondence: [email protected]. Links Database of the human metabolic network:humanmetabolism.org Status of Cancer clinical trials in the United States: cancer.gov/clinicaltrials Encyclopedia of metabolic pathways: metacyc.org Human Metabolite Database: hmdb.ca Jason Locasale's website: Jlocasale.human.cornell.edu Metabolomics resources on behalf of Dr. Gary Siuzdak's lab: metlin.scripps.edu National Institutes of Health initiative on metabolomics: commonfund.nih.gov/Metabolomics/ Timeline 1944 ± Soldiers in the Pacific Islands with tropical anemia are treated with B vitamins.
    [Show full text]
  • The Export of Polyamines in Plants Is Mediated by a Novel Clade of Bidirectional Transporters
    THE EXPORT OF POLYAMINES IN PLANTS IS MEDIATED BY A NOVEL CLADE OF BIDIRECTIONAL TRANSPORTERS Lingxiao Ge A Dissertation Submitted to the Graduate College of Bowling Green State University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY August 2015 Committee: Paul Morris, Advisor Nancy Ann Orel, Graduate Faculty Representative Vipa Phuntumart Ray Larsen Scott Rogers ii ABSTRACT Paul Morris, Advisor Ubiquitously existent in nature, polyamines play an important role as signaling compounds in plant responses to both biotic and abiotic stresses. My research has shown that the clade of Arabidopsis thaliana and rice BIDIRECTIONAL AMINO ACID TRANSPORTERS (BAT) function as antiporters of polyamines and amino acids. The method used in this study takes advantage of the genetic resources of the model organism Escherichia coli. A double knockout E. coli strain that is deficient in all polyamine antiporters was created and then used to heterologously express candidate plant transporters AtBAT1.1, AtBAT1.2, and OsBAT1. Inside- out membrane vesicles of these transgenic E. coli cells were generated by ultrasound sonication or French press. A radioisotope assay was then performed using these vesicles to confirm the specificity of the target proteins as polyamine antiporters. To determine the role of BATs in polyamine homeostasis we tested their GFP fusions by transient expression in Nicotiana benthamiana. The GFP-tagged AtBAT1 and OsBAT1 displayed plastid localization in tobacco leaves by using confocal microscopy. Furthermore, the overexpression of OsBAT1 in A. thaliana wild-type results in novel phenotypes that could have potentially economical usage. This indicates that by altering the expression of a single gene of polyamine transporter, we can manipulate the plants phenotypes similar to natural variations.
    [Show full text]